The FDA approved the drug to reduce the risk of heart attack and strokes in people with cardiovascular disease who are overweight or obese. Currently, Medicare is prohibited by law from covering Wegovy and other medications when used specifically for obesity.
A KFF analysis of Medicare data from 2020 estimated that 3.6 million — or 7% of — beneficiaries had established cardiovascular disease and were obese or overweight. These people represent 26% of Medicare beneficiaries diagnosed as being overweight or obese. Of the 3.6 million, 1.9 million also had diabetes and may already be eligible for Medicare coverage of GLP-1s.
Some Part D plans have already announced that they will begin covering Wegovy this year, though it is not clear how widespread the coverage will be.
Based on the current list price of $1,300 per month, Medicare beneficiaries may be required to pay $325 to $430 per month before they would reach the new cap on annual out-of-pocket drug spending.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.